Anti-Hsp90 beta抗体[H90-10] (ab53497)

Thank you for your reply. I will forward your request to 51AB, who will be in contact with you to process your refund request. I hope this information is helpful.  Please do not hesitate to contact us if you have any additional questions.

Than you for your inquiry and I am sorry to hear that you are experiencing some trouble with ab53497 and ab79849. Are you running any isotype controls with these experiments? I just want to make sure that the pull down with the HBP21 antibody is genuine. Have you tried to do a regular IP and not a co-IP with ab53497 and ab79849? These are the IP references we know of with the HSP beta antibody, ab53497. Barent R. L. (1998) Mol. Endocrinol. 12: 342-354 11. Lo. M.A. (1998) EMBO J. 17: 6879-6887. What kind of lysis buffer are you using? A key factor in maintaining complex formation throughout the steps required for co-IP is the lysis and wash buffers. Many protein interactions will remain intact after lysis using standard non-denaturing lysis buffers. Buffers with low ionic strength (i.e., <120mM NaCl) that contain non-ionic detergents (NP-40 and Triton X-100) are less likely to disrupt protein-protein interactions; however, testing may be required to determine the best buffer formulation for a specific protein complex of interest. Additionally, lysing cells by sonication or vortexing the lysate or bead-bound immune complexes during the wash steps should be avoided to prevent the disruption of the protein-protein interaction(s) of the target complex. And while centrifugation is a standard method to separate the precipitated complexes from the remaining lysate and during wash steps, the samples should be handled gently to prevent the loss of bound complex proteins. An advanced technique to strengthen protein-protein interactions is by crosslinking the binding partners. Using this approach, all proteins within the active distance of the specific reagent in a cell lysate are covalently crosslinked, and the target protein can then be immunoprecipitated along with the other proteins in the complex without the risk of losing binding partners. Co-IPs can be tricky due to the nature of the interaction of the proteins, nonspecific binding to IP components and antibody contamination that may mask detection. We haven't tested ab53497 and ab79849 by co-IP so it's difficult to know if this may be the issue. Could you try the protocol recommendations or run a regular IP with the antibody? That could show that it is an issue with the protein binding more than the antibodies.